Short answer: on 24 July 2026 the Food Safety and Standards Authority of India told the market that nicotinamide mononucleotide is an unapproved ingredient for food-supplement use in India, and that NMN products listed on e-commerce platforms should come down [1][2]. That is not the same instrument as scheduling NMN as a prohibited substance, and the difference matters when you write the compliance file: what India changed is market access pending approval, not the molecule’s safety classification. Nothing in it touches a shipment going to New Jersey, Rotterdam or Tokyo. The exposure it does create for an exporter is documentary. NMN’s legal status now differs by gateway across the markets you sell into — cleared by notification in the US, under authorisation in the EU, unapproved in India, split by product category in China — so the thing that protects a shipment is not a certificate of analysis but a traceability chain that ties one lot to one named approval. This article maps ten markets, states what each one requires, marks what we could not verify, and gives the document architecture that survives an audit.
Key takeaways
- “Ban” names the wrong instrument. The Indian action is an unapproved-ingredient determination plus a listing takedown direction. It blocks manufacture and sale for the domestic supplement market until an approval exists; it does not declare the substance hazardous, and it does not prohibit export, research use or other regulated uses.
- Status is gateway-dependent, not molecule-dependent. The same drum can be a cleared dietary ingredient under a US notification, an unauthorised novel food in the EU, an unapproved supplement ingredient in India and a cosmetic ingredient in China — at the same time, on the same CoA.
- Secondary sources disagree, loudly. On China alone, current commentary ranges from “approved new food ingredient” to “cosmetics only.” Treat any status you cannot trace to a regulator’s own register as unconfirmed — including statements in this article.
- Liposomal adds a compliance layer, not only a performance layer. The carrier is part of how a material is described. Encapsulation efficiency, lecithin source, particle size and residual solvent all become audit questions, and an approval written for the free molecule may not describe your dispersion.
- Traceability is the mitigation. Six links from feedstock to market file, seventeen records with named owners, and change control that treats a route change as a re-submission event rather than an internal note.
What the FSSAI notice does — and does not do
Read the instrument before you read the headline about it. On the reporting available to us, the FSSAI communication of 24 July 2026 does four things: it states that NMN is not an approved ingredient for supplement use in India; it directs that NMN products sold through e-commerce platforms be removed; it points companies who want to market NMN toward the approval route for non-specified food and food ingredients; and it sits inside a visible 2026 enforcement sequence on supplement labelling that reached large brands and marketplace operators in October [1][2][7].
Four readings that circulate on the back of that notice are not supported by it: that NMN has been placed on a prohibited or poisoned-substance schedule; that the Indian action reaches product sold in other jurisdictions; that a consumer-level recall has been ordered, which nothing in the reporting we could reach states; and that the notice settles the status of NMN in cosmetic, research or pharmaceutical contexts, which run through different gates entirely.
Figure 2. The instrument and the misreading, side by side. We did not obtain the notice text itself; the left column follows reported content and the structure of Indian food law.
Why “unapproved” is the operative word. India’s supplement framework runs on permitted schedules: the Health Supplements and Nutraceuticals Regulations list the ingredients a supplement may contain, and anything outside them needs an approval for non-specified food and food ingredients before it can be used [8][11]. A material can be thoroughly studied, widely sold abroad and completely safe in a toxicological sense, and still be unmarketable there because its name is not in a schedule. That is the mechanism behind the 24 July notice, and it explains the detail that matters most to a supplier: reporting on the notice states that six approval applications for NMN had been rejected and two were pending [12]. This is not a chemistry dispute. It is a queue.
Corroboration comes from an unlikely place. One of the Indian brands named in the action published its own account: it says it applied for NMN approval in July 2024, that the application remained under consideration, that it responded to the 24 July notice on 28 July, and that it is not treating the pending application as permission to keep selling — suspending fresh manufacture, packing, dispatch, sale, advertising and promotion, instructing marketplaces and distributors to delist, blocking and quarantining available stock, and starting a batch-wise reconciliation and retrieval [13]. Read that last phrase again, because it is the whole of this article in four words: batch-wise reconciliation is only possible for a company that can tie every filled container back to a lot, a route and a document.
How we know, and how far that goes. The date and content come from industry reporting rather than from the notice document, which we did not obtain for this article. That is a real limitation, and it is why the tables below separate reported from confirmed in a regulator’s own register. If a commercial decision depends on the exact wording, pull the notice from FSSAI’s site or have Indian counsel pull it. Do not rely on this page, or on a competitor’s blog, for the text of a regulator’s instrument.
Four years of status changes, in one table
The reason a compliance map ages badly in this category is that the reference points keep moving. Below is the sequence we could evidence, with the instrument each event touched. Dates are publication or announcement dates.
Figure 1. NMN regulatory events, May 2022 to August 2026. Green marks an expansion of market access; amber marks a contraction or an unresolved outcome.
| Date | Market | Event | Instrument touched | Evidence |
|---|---|---|---|---|
| May 2022 | United States | Two NMN new dietary ingredient notifications accepted | FD&C Act notification | Reported [3] |
| Nov 2022 | United States | FDA withdraws its position; drug-preclusion clause applied | DSHEA drug preclusion | Reported [3] |
| 1 Jul 2024 | India | Approval route for non-specified food and ingredients re-operationalised | FSS non-specified food framework | Reported [8][10] |
| Late Sep 2025 | United States | FDA reverses the exclusion of NMN | DSHEA drug-preclusion reading | Reported [3] |
| Dec 2025 | United States | FDA letters reinstate the notified NMN ingredients | Notification correspondence | Reported [3] |
| 11 May 2026 | European Union | EFSA safety opinion on beta-NMN as a novel food for supplements | Regulation (EU) 2015/2283 | Journal article [4] |
| 24 Jul 2026 | India | FSSAI notice: unapproved for supplement use; listings removed | FSS supplement rules | Reported [1][2] |
| Aug 2026 | China | Cosmetic ingredient inventory updated; food status reported inconsistently | IECIC / NHC new food ingredient | Reported, conflicting [9] |
Two structural points fall out of that table. First, an ingredient can lose and regain a market inside a single product lifecycle: the US gap between November 2022 and late 2025 was roughly three years, long enough to write off a formulation programme and a set of label plates. Second, the EU row is the one most often misread in planning. A positive safety opinion is not market access — it says a dossier was assessed. Only entry on the Union list says you may sell [4][5]. Teams collapse those two dates into one in their own notes and then plan a launch against a date that does not yet exist.
Ten markets, five different answers
The map is the working version we would use to screen an enquiry, not a register of law. Two columns matter more than the status column: instrument, because it tells you which document answers the question, and how we know, because it tells you how much weight to put on the status. Rows marked verify name the correct gateway but were not confirmed against the regulator’s own register during our November 2026 check. They are there to tell you what to go and check, not to let you skip checking.
Figure 3. The compliance map. Four rows carry a status we could evidence; six are marked verify because the current position could not be confirmed from a primary source.
| Market | Instrument that decides it | Status we could evidence | How we know | Document a buyer should hold |
|---|---|---|---|---|
| United States | DSHEA; new dietary ingredient notification; drug-preclusion clause | Cleared where a notification covers the material | Reporting of FDA correspondence, Dec 2025 [3] | The notification reference, or the supplier’s written statement of which notification their material falls under |
| European Union | Regulation (EU) 2015/2283 on novel food | Assessed, not yet authorised | EFSA opinion May 2026 [4]; Commission application register [5] | Union list entry, or the applicant’s letter of access if you rely on their dossier |
| United Kingdom | FSA novel food catalogue and status letters | verify | Separate UK regime after Brexit; not confirmed from the FSA register | Catalogue entry or a written status letter |
| India | FSS Act 2006; supplement rules; non-specified food approval | Unapproved for supplement use | FSSAI notice reported 3 Aug 2026 [1][2] | Prior FSSAI approval. Without it, do not ship for the supplement market |
| Canada | Natural Health Products Regulations; site and product licences | verify | Instrument known; position in the licensed-product database not checked | Eight-digit licence number plus the manufacturing site licence reference |
| Australia / New Zealand | Food Standards Code Standard 1.5.1; TGA for listed medicines | verify | FSANZ publishes a record of views [6]; the NMN entry was not confirmed | Record of views or approval, plus the medicines-classification decision |
| Japan | Food Sanitation Act; FFC claim regime | Long food-use history; claims policed separately | General regime; the 2026-specific position was not re-verified | Claim substantiation file if you make functional claims |
| China | NHC new food ingredient announcements; IECIC for cosmetics | Split, and inconsistently reported | 2026 cosmetic inventory update reported [9]; food-status sources conflict | For food: the announcement number. For cosmetics: the IECIC entry and its use limit |
| South Korea | MFDS functional ingredient positive list | verify | Instrument known; the listing reference was not confirmed | Listing reference covering the exact form and specification |
| Singapore / Gulf | SFA novel food notification; Gulf registration | verify | Mechanism documented by the regulators; NMN-specific outcome not checked | Notification acknowledgement or the registration certificate |
Read the verify rows together rather than individually. A row can be entirely correct on instrument and still be commercially useless: knowing that Canada runs a product-licence system tells you nothing about whether a given NMN SKU holds a licence number. That is why the final column is written as a document rather than a verdict. Documents can be requested, checked and filed. Verdicts go stale on a Tuesday without notifying anybody.
Why regulators reach different answers on the same powder
Four variables, rather than four opinions, generate most of the divergence on the map.
1. Which way round the gate is built. The US model is notification plus enforcement: you declare, and the agency acts if it disagrees. The EU, UK and ANZ models are pre-market approval: nothing moves until a list changes. India’s supplement framework sits closer to the second family for ingredients it has not already contemplated, which is exactly why an “unapproved” finding produces a market closure rather than a warning letter. Same molecule, opposite default.
2. Prior marketing and drug preclusion. The US sequence from 2022 to 2025 turned on whether a molecule had been investigated as a drug before it was lawfully marketed as a food — a question that exists in that statutory form in almost no other market [3]. Reading US headlines as a global signal is the most common exporter error: the 2025 reversal changed an American interpretation of one clause, not the ingredient.
3. History of consumption. Novel-food systems ask whether a food was eaten to a meaningful degree before a cut-off date. Materials with a documented food history clear a bar that a newly isolated NAD+ precursor cannot, which is one reason the same category lands so unevenly across Asia and Europe.
4. Which box the product sits in. China is the clean illustration: 2026 reporting places NMN in the cosmetic ingredient inventory while leaving the food question separate and, in secondary commentary, actively contradictory [9]. From outside, a regulator deciding two categories on two timetables looks like a contradiction. From inside, it is two files, two fees and two clocks.
Figure 4. One bag of powder, five legal realities. Each branch is decided by a different institution on a different timetable, which is why a single specification sheet cannot serve a multi-market programme.
The layer a molecule-only compliance view misses
Almost all NMN compliance commentary is written about the molecule. Exporters do not ship molecules; they ship a described material, and a liposomal ingredient carries more description fields. Every extra field is another place where a document can fail to match.
- The carrier is part of the identity. A notification written for crystalline NMN describes a substance. A liposomal powder is a substance plus a structure: phospholipid source, aqueous-core payload, encapsulation efficiency, particle-size distribution, residual solvent. Ask whether the approval text describes the free molecule or the encapsulated material.
- Lecithin source is a labelling decision in three markets at once. Soy and egg derivatives trigger allergen declaration in the EU, US and UK; a sunflower source shifts the picture and can change the claim set. When carrier source changes, the label changes — that is never purely a supplier-internal event.
- Encapsulation efficiency is a claim, so it needs a method. A number quoted without an assay method is marketing text. Once a buyer copies it into a specification, it becomes a contractual term with no evidence behind it.
- Particle size invites a nanomaterial question. Where a regime applies nano-specific requirements, the answer turns on the measured distribution and the primary particle population — not on the vesicle diameter in a datasheet. Keep the light-scattering report with its dilution protocol on file for exactly this question.
- Format and dose are scoped. Capsule, sachet and ready-to-drink are frequently separate use conditions, and the maximum per-serving level in an approval can sit below the dose your finished product targets. Read the number; never inherit it from a competitor’s label.
Figure 7. Scope dimensions. Every approval writes its own limits; this is the shape of the question to put to a document, not a summary of any single authorisation.
Traceability is the only part you control
You cannot move a regulator’s calendar. You can control whether a specific lot can be tied, in writing, to a specific legal basis — and whether that tie survives a change. That is the whole of what a traceability strategy buys: the ability to answer an audit question with a document instead of a recollection.
Figure 6. The chain, with the record type each link must produce. Links 1 to 4 are normally supplier-owned; links 5 and 6 sit with the brand or importer.
What a delisting order actually asks of your records
Most exporters read a notice like this as a sales problem. For anyone holding stock, in transit stock or a co-manufacturing slot, it is a records problem with a clock on it. The sequence an affected company has to execute is fixed: identify every lot containing the ingredient, locate every container those lots reached, stop further movement, notify the parties holding the goods, reconcile what is unaccounted for, and be able to show a regulator that the boundary of the exposure is known. Each of those steps is a document question, and every one of them is answered from the chain, not from the certificate of analysis.
Companies that buy on price alone discover the cost at exactly this moment. A lot recorded only as “NMN powder, 500 g/batch” cannot be reconciled batch-wise, so the boundary cannot be drawn, so the exposure is everything. A lot recorded against a route, a carrier batch, a CoA number and an approval reference can be bounded in an afternoon.
The seventeen records, grouped by who owns them
Asked for one at a time, these look like vendor paperwork. Assembled against a lot number, they are the defence file — and the third column is where late surprises live, because authority-issued documents usually belong to the importer, not to the factory.
Figure 5. Who owns which record. Build the map before the first purchase order, not after the first customs query.
Four clauses that carry the weight
All four are cheap before an order and expensive afterwards.
- Named legal basis. The contract states which notification, listing or approval the delivered material is intended to satisfy, by reference number. Not “complies with all applicable regulations.”
- Advance change notification. Written notice before shipment of any change to synthesis route, raw-material source, carrier source, specification or manufacturing site, with a right to re-qualify or reject.
- Lot-matched evidence. Certificates of analysis and particle-size reports issued for the shipped lot, not a typical figure or a development batch.
- Allocation on status change. What happens to in-transit and committed stock if a market moves between order and arrival. The US history from 2022 to 2025 shows this is not hypothetical.
Pre-shipment verification, in five steps
Run this before you quote a delivery date, not once the container is packed.
- Name the gateway. Write down the instrument in the destination market — notification, novel food listing, product licence, non-specified food approval, cosmetic inventory entry. If you cannot name it, you are guessing.
- Get the document, not the assurance. “FDA approved” is not a document; a reference number, list entry or licence number is. For EU reliance on somebody else’s dossier, the letter of access is the instrument.
- Match scope line by line. Identity and route, specification, use level, food category, carrier and format, applicant and access. Five of six are usually fine; the sixth is where the shipment stops.
- Freeze the chain. Fix route, carrier source and specification for the qualified period, and treat any change as a re-submission event rather than an internal note in a batch record.
- Set a review date. For an ingredient whose status moved three times in four years, a compliance map older than one quarter is a hypothesis. Put the date on the file and diarise the review.
What this article cannot tell you
Read this before you act on anything above. This is a technical and commercial briefing written by an ingredient supplier, not legal advice, and it has four specific limits.
One: we did not obtain the FSSAI notice text. The description of it here follows reported content; if a decision depends on wording, obtain the instrument itself. Two: six of the ten market rows are marked verify because we could not confirm the current position against the regulator’s own register in a November 2026 check — they tell you which door to knock on, not what is behind it. Three: China’s food-versus-cosmetic reporting is genuinely inconsistent across secondary sources at the time of writing, and we have not resolved it; the same is true of any status you read on a vendor blog, including this one. Four: statuses in this category have moved three times since 2022, so every row is dated. Re-check before you quote a delivery date, and put counsel in the loop for the market you actually ship to.
Frequently asked questions
Is NMN banned in India?
Not in the sense most readers assume. Reporting on FSSAI’s notice of 24 July 2026 describes NMN as an unapproved ingredient for food-supplement use, with e-commerce listings directed to be removed and market entry conditioned on an approval. That closes the domestic supplement market. It is not the same instrument as placing a substance on a prohibited list, and it does not describe the molecule as hazardous.
Does the Indian action affect NMN we export to the US or Europe?
No. FSSAI administers Indian food law. A shipment to a US or EU customer is governed by that destination’s instrument — a new dietary ingredient position in the US, a novel food status in the EU. What India does change is portfolio planning: if India was in your twelve-month forecast, that forecast needs an approval milestone in it before it is credible.
Can we still sell NMN in India for cosmetic or research use?
Those run through different gates and are not decided by a food-supplement notice. Cosmetic use in India sits with the drugs and cosmetics authority rather than FSSAI, and research-grade material has its own supply conditions. Confirm each separately with local counsel; a food notice does not answer them.
What is EFSA’s 2026 opinion worth commercially in the EU?
It is a safety assessment, not a permission to sell. Under Regulation (EU) 2015/2283, a novel food may be placed on the market once it is authorised and enters the Union list. An opinion without a Commission act leaves you in the pre-authorisation position, which for a distributor is the same as nowhere.
Does a liposomal form change the regulatory question?
It adds fields to it. Approvals describe a material, and a liposomal ingredient has a carrier, an encapsulation efficiency, a particle-size distribution and a residual-solvent profile that the free molecule does not. Ask whether the approval you are relying on describes the encapsulated material, and check the carrier’s own food-use and allergen status in the destination.
How often should we re-check a compliance map like this one?
Quarterly as a floor for an ingredient whose status has moved repeatedly, and immediately on three triggers: a new destination market, a change of synthesis route or carrier source, and any change to your per-serving dose. Each of those can move you from “documented” to “unsubstantiated” without a single line of chemistry changing.
What is the single most useful document to ask a supplier for?
The one that names a legal basis by number: a notification reference, a listing entry, an approval number, or a letter of access to someone else’s dossier. Anything that says “fully compliant worldwide” without a number is a marketing claim, and if you have copied it into your specification you have converted it into a contractual term you cannot evidence.
Who owns the traceability chain, supplier or brand?
Split, and the seam is where audits fail. Links from feedstock to liposomal lot are normally supplier-held; links from finished format to the market file are the brand’s. Both need to name the same lot number, which means the handover has to be designed rather than assumed. Put it in the contract.
Sources
Links were checked on 13 November 2026. Two carry a note: the NutraIngredients pages returned a bot-block to our checker and should be opened in a browser, and the FSSAI PDF is a 2022 direction that supplies the legal mechanism rather than the 2026 notice itself. Where a status matters commercially, go to the register named in the last column of the map rather than to this list.
- FSSAI notice states NMN is an unapproved ingredient for supplement use in India, with e-commerce takedown direction — NutraIngredients, 3 August 2026. nutraingredients.com
- Regulatory review covering NMN in India, GMP rules in South Korea and probiotics in China — NutraIngredients, 17 August 2026. nutraingredients.com
- FDA letters reinstating NMN as a lawful dietary ingredient, with the 2022 notification and withdrawal history — SupplySide Supplement Journal, 10 December 2025. supplysidesj.com
- EFSA scientific opinion on the safety of beta-NMN as a novel food for food supplements — EFSA Journal, 11 May 2026. efsa.onlinelibrary.wiley.com
- Summary of novel food applications submitted under Article 10(1) of Regulation (EU) 2015/2283 — European Commission. food.ec.europa.eu
- Record of views formed in response to inquiries, Standard 1.5.1 Novel Foods — Food Standards Australia New Zealand, updated February 2026. foodstandards.gov.au
- FSSAI notices to named brands and marketplace operators over supplement labelling claims — Mint, 8 October 2026. livemint.com
- FSSAI list of products and ingredients approved under the non-specified food and food ingredient framework — Food Safety and Standards Authority of India. fssai.gov.in
- China’s IECIC II cosmetic ingredient inventory update in 2026 — REACH24H regulatory update, 25 August 2026. en.reach24h.com
- Re-operationalisation of the Indian non-specified food approval process from 1 July 2024 — Food Compliance International, 2 September 2024. foodcomplianceinternational.com
- FSSAI direction operationalising the Health Supplements and Nutraceuticals Regulations, which set the permitted-ingredient schedules — Food Safety and Standards Authority of India, 30 March 2022. fssai.gov.in
- Record of the Indian action on NMN, including the count of rejected and pending approval applications — Blacklisted regulatory-record database, last checked 10 October 2026. blacklisted.co.in
- Statement from one of the brands named in the notice: suspension of manufacture and sale, marketplace delisting instructions, stock quarantine and batch-wise reconciliation — Decode Age, updated 9 September 2026. decodeage.com
Related EmerWell pages
- Liposomal NMN powder import guide for global buyers
- Liposomal NMN powder certifications for B2B sourcing
- What certifications should I look for when selecting liposomal NMN powder?
- What to check in a liposomal NMN powder CoA
- How to evaluate liposomal NMN powder quality
- Best liposomal NMN powder supplier: 7 checks to make
- How is liposomal NMN powder made: a process guide
- Liposomal NMN powder: stability testing and storage
- Liposomal NMN Powder — product specification
Written by the EmerWell Formulation Science Team. The team works on lipid-based delivery systems, scale-up and the documentation that accompanies both, for supplement brands and contract manufacturers.
Review: technical review against current batch documentation held by the EmerWell QA group. Disclosure: EmerWell manufactures and sells the liposomal ingredients discussed. This article was written to help buyers specify and defend a supply decision; every regulatory statement is attributed to a dated source, and rows we could not confirm are marked as unconfirmed rather than resolved. It is not legal or regulatory advice, and it takes no account of your specific product, market or claims.
Bring a compliance file, get a supply answer
Tell us the destination market and the finished format. We will return the documentation pack that matches that gateway — lot-matched certificate of analysis, encapsulation-efficiency report by method, particle-size distribution with dilution protocol, phospholipid source and allergen statement, residual solvent declaration and site licences — and we will say plainly which parts of your regulatory question a supplier can answer and which belong with your counsel.
Request the export documentation pack | info@emerwell-bio.com